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Sterically Stabilized Liposomes Labeled with 
Indium-111 to Image Focal Infection
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To determine the potential of sterically stabilized liposomes to 
image infectious and inflammatory foci, the in vivo behavior of 
1111n-labeled PEGylated (coated with polyethylene glycol) lipo­
somes was studied in a rat model. Methods: Indium-111- 
PEGylated lipsomes were administered intravenously to rats 
infected with S. aureus in the left calf muscle. The distribution of 
the radiolabel was studied by gamma counting of dissected 
tissues and gamma camera imaging for 48 hr. As a reference 
agent, the preparation of i11ln-lgG was included in these stud­
ies. Results: Clearance of the PEGylated liposomes from the 
blood compartment was similar to the clearance of 111ln-lgG in 
this model (t1/2 -  20 hr). Uptake of the radiolabel in the abscess 
with the111 ln-!iposomes was twice as high as the uptake follow­
ing injection o f1111n-IgG (2.7 %ID/g versus 1.1 %ID/g at 48 hr 
postinjection). Tissue counting revealed that abscess-to-muscle 
ratios reached values up to 20 and 34 (24 and 48 p.L, respec­
tively). As early as 1 hr postinjection, the abscess could be 
visualized scintigraphically. Conclusion: The in vivo character­
istics of this liposomal formulation in this rat model indicate that 
sterically stabilized liposomes labeled with gamma emitters 
might be a valuable addition to the arsenal of radiopharmaceu­
ticals currently used for infection imaging.
Key Words: indium-111-PEGylated liposomes; sterically stabi­
lized liposomes; infection imaging
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T
-■—localization of infectious and inflammatory lesions is a 
challenging goal in nuclear medicine, as it may have im­
portant implications for the management of patients. Over 
the last two decades, numerous radiopharmaceuticals have 
been developed and clinically investigated. Each of these 
techniques, although successful in many cases, has its par­
ticular disadvantages {1,2). Recently, we formulated char­
acteristics of the ideal radiopharmaceutical for the detec­
tion of sites of infection and inflammation (3). In view of 
the limitations of each of the conventional radiopharma-
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ceuticals, there is a continued search for safe agents that 
will rapidly visualize foci of infection and inflammation 
with high degrees of sensitivity and specificity.
Liposomes are microscopic lipid vesicles consisting of 
one or more concentric lipid bilayers enclosing discrete 
aqueous spaces. Liposomes have been investigated exten­
sively as carriers for drugs in attempts to achieve selective 
deposition and/or reduced toxicity {4-6). Liposomes, as 
formulated in the past, are rapidly taken up by cells of the 
mononuclear phagocyte system (MPS), primarily those lo­
cated in the liver and spleen. This natural targeting could 
be heightened by increasing the vesicle size and/or includ­
ing negatively charged lipids (e.g., phosphatidylserine) into 
the bilayers. Enhanced efficacy of macrophage-activating 
factors and drugs directed against pathogens residing 
within MPS cells of the liver and spleen has clearly been 
demonstrated {7,8). Due to their rapid association with 
MPS cells, however, liposomes showed inefficient target­
ing to other tissues in vivo. In recent years, the develop­
ment of new formulations of long-circulating liposomes 
(also referred to as Stealth* or sterically stabilized lipo­
somes) has greatly broadened the potential applications of 
liposomes for targeted delivery. Because sterically stabi­
lized liposomes show reduced uptake by MPS cells, and as 
a consequence, prolonged circulation times, the opportu­
nity for targeting to other tissues is enhanced. The recent 
observations with these novel liposomes showing en­
hanced localization in tumors (9,10) and sites of infection 
{11,12) confirm the improved outlook for targeted liposo­
mal delivery. At present, small (about 100 nm or less) 
liposomes containing hydrophilic phosphatidylethanola- 
mine (PE) derivatives of polyethylene glycol (PEG) appear 
to show the best performance in terms of prolonged circu­
lation and reduced MPS uptake as compared to other long- 
circulating liposomes (13).
Conventional liposomes labeled with gamma-emitting 
radionuclides have been used succesfully for scintigraphic 
imaging of infection (14) and inflammation (15-17). We 
hypothesized that reduced MPS uptake of sterically stabi-
*Stealth liposomes is a registered trademark name of Liposome Technology, 
Inc., Menlo Park, CA.
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lized liposomes will improve their localization in the infec­
tious focus. Therefore, we studied the biodistribution of 
m In-labeled PEGylated liposomes in rats with focal S. 
aureus infections. The preparation of m In-IgG was in­
cluded in these studies as a reference to estimate the clin­
ical potential of PEGylated liposomes as an imaging agent.
MATERIALS AND METHODS 
Liposome Preparation
Partially hydrogenated egg-phosphatidylcholine with an iodine 
value of 40 (PHEPC) was prepared as previously described (18), 
The polyethyleneglycol (PEG) 1900 derivative of distearoylphos- 
phatidyl-ethanolamine (PEG-DSPE) also was prepared as previ­
ously described (29).
A  lipid mixture in chloroform/methanol (10/1, v/v) was pre­
pared with the mole ratio composition of 0.15:1.85:1 (PEG-DSPE/ 
PHEPC/cholesteroI). A  lipid film was formed by rotary evapora­
tion followed by high vacuum to remove residual organic solvent. 
The lipids were dispersed at room temperature in 6 mM  Desferal 
in 0.9% HEPES buffer (10 mM  HEPES, 135 mM NaCl, pH 7.5) at 
an initial phospholipid concentration of 120 mM, The resultant 
multilamellar vesicles were sized by bath sonication for 2 hr. 
Unentrapped deferoxamine mesylate (Desferal) was removed by 
cation exchange resin Dowex 50WX4 (20). The particle size dis­
tribution was determined by dynamic light scattering. The lipo­
somes had a mean size of 90-100 nm.
Labeling Procedures
Preformed Desferal containing liposomes were labeled with 
m In essentially as previously described (12,21). Indium-111 was 
transported by hydroxyquinoline (oxine) through the bilayer and 
trapped irreversibly in the internal aqueous phase by the encap­
sulated Desferal. Briefly, the liposomes (75 ¡imole phospholipid/ 
ml) were incubated for 1 hr at room temperature with 2-3 jiCi 
m In-oxine per /¿mole phospholipid. Unencapsulated ulIn-oxine 
was removed by gel filtration on a 10DG Econo Pak column 
(Bio-Rad, Richmond, CA). More than 75% of the U1ln label was 
entrapped within the liposomes.
Human, nonspecific polyclonal IgG was conjugated to diethyl- 
enetriaminepentaacetic bicyclic anhydride (bicyclic DTPA) ac­
cording to the method described by Hnatowich et al. (22) and 
labeled with m In. Labeling efficiency as determined by ITLC was 
higher than 95%.
Animal Model
A  calf muscle abscess was induced in young, male, randomly 
bred Wistar rats (weight 200-220 g). After ether anesthesia, ap­
proximately 2 x 108 colony forming units of S. aureus in 0.1 ml 
50:50% suspension of autologous blood and normal saline were 
injected in the left calf muscle (25). Twenty-four hours after the 
inoculation, when swelling of the muscle was apparent, the re­
spective radiopharmaceuticals were injected through the tail vein.
Biodistribution Studies
Twenty-four hours after S. aureus inoculation, 30 rats were 
divided randomly into two groups. One group of 15 rats was 
injected with 400 kBq 1 u In-liposomes through the tail vein. As a 
control, the other group of rats received 400 kBq (=25 /xg) m In-
IgG.
At 2, 24 and 48 hr postinjection, five rats in each group were 
killed with 30 mg intraperitoneally injected phenobarbital. Blood 
was obtained by cardiac puncture. Following cervical dislocation,
several tissue samples (infected left calf muscle, right calf muscl< 
liver, spleen, kidney, intestine, right femur and bone marrow froi 
the right femur) were dissected, weighed and their activity wa 
measured in a shielded well-type gamma counter. To correct fc 
physical decay and to calculate radiopharmaceuticals uptake i 
each organ as a fraction of the injected dose, aliquots of th 
injected dose were counted simultaneously.
Imaging Protocol
S. aureus infection was induced in another six rats as describe' 
above. Twenty-four hours later, three rats received 4 MBq m In 
liposomes through the tail vein. For comparison, the other thre 
rats received 4 MBq m In-IgG. Rats were anesthesized (halo 
thane/nitrousoxide) and were placed prone on a single-heai 
gamma camera equipped with a parallel-hole, medium-energy col 
limator. The two groups of rats were imaged synchronously at: 
min, 0.5, 1, 2, 4, 6, 24 and 48 hr postinjection. Symmetric 209> 
windows were used for both the 173- and 247-keV energy peaks 
Images (300,000 cts/image) were obtained and stored in a 256 > 
256 matrix. After 48 hr, the animals were killed and dissected t( 
determine the biodistribution of the radiolabel.
The scintigraphic results were analyzed by drawing regions o 
interest over the abscess, the normal contralateral calf muscle 
used as a background region, and over the whole animal. Abscess 
to-background ratios and the percentage of residual activity in the 
abscess (abscess-to-whole body ratio) were calculated.
Statistical Analysis
All mean values are given ± 1 s.d. Statistical analysis was 
performed using the unpaired two-tailed Student’s t-test.
RESULTS
The biodistribution of in In-labeled PEGylated lipo­
somes and u lIn-IgG in rats with S. aureus infections are 
shown in Table 1. Blood levels of u lIn following injection 
of both radiopharmaceuticals were similar. Localization in 
the abscess increased over the time course of the experi­
ment, from 0.7% ID/g at 2 hr postinjection to 2.7% ID/g at 
48 hr postinjection. Both the increase over the 2-24-hr 
period (p < 0.002) as well as the increase over the 24-48-hr 
(p < 0.03) were statistically significant. Abscess uptake of 
the lllIn-liposomes was approximately twice as high as 
lu In-IgG uptake (24 and 48 hr postinjection, p < 0.005).
Besides accumulation in the abscess, a marked accretion 
of the liposomal radiolabel was observed in the spleen over 
the 48-hr time period. Mean uptake rose to 16% ID/g at 48 
hr, indicating that almost 10% of the injected dose accu­
mulated in the spleen. The liver, which together with the 
spleen is the major organ with mononuclear phagocytic 
activity, showed less pronounced accumulation; during the 
last 24 hr of the experiment, there was a slight but signifi­
cant increase of ln In activity in the liver (from 0.9% to 
1.4% ID/g; p < 0.003). Separate measurement of the activ­
ity in the right femur and the bone marrow indicated an 
increase of activity in the bone marrow as well (from 1.2% 
to 2.0% ID/g; p < 0.005). All other tissue samples exam­
ined had low activity levels which decreased with time. 
Except for the spleen, the abscess was the tissue with the 
highest activity from 24 hr onwards.
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TABLE 1
Biodistribution of Indium-111 -PEGylated Liposomes and Indium-111 -IgG in Rats with S. aureus Infections in Calf Muscle
(%ID/g ±  s.d.)
Organ
Blood
Muscle
Abscess
Bone marrow
Bone
Lung
Spleen
Kidney
Liver
Small intestine
2 hr p.i.
Liposomes
4.45 ± 0.26 
0.10 ±0.04 
0.73 ± 0.16 
1.19 ± 0.20 
0.30 ± 0.09 
1.18 ±0.21 
4.32 ± 0.51 
1.11 ±0.16 
1.27 ± 0.41 
0.42 ± 0.08
IgG
3.75 ±0.15 
0.13 ±0.03 
1.10 ±0.14 
1.54 ±0.13 
0.56 ±  0.08 
1.12 ± 0.14 
1.26 ±0.53
4.40 ±0.16
1.40 ±0.10 
0.38 ± 0.04
24 hr p.i.
Liposomes
2.00
0.10
1.93
1.58
0.38
0.64
11.66
0.84
0.89
0.65
0,06
0.01
0.54
0.29
0.13
0.07
0.98
0.07
0.14
0.09
IgG
1.30 ± 0.1 
0.15 ±0.02 
0.97 ± 0.04
1.30 ± 0.08 
0.35 ± 0,03 
0.54 ± 0.05 
1.56 ± 0.19 
4.78 ± 0.34 
1.11 ± 0.10 
0.23 ± 0.03
48 hr p.i.
Liposomes
0.84 ±0.13 
0.09 ± 0.02 
2.73 ± 0.38 
2.04 ± 0.46 
0.29 ±0.17 
0.51 ± 0.34 
16.12 ±4.07 
0.71 ±0.10 
1.44 ± 0.24 
0.80 ±0.12
IgG
0.95 ±0.15 
0.15 ±0.01
1.10 ±0.09
1.11 ±0.06 
0.33 ± 0.04 
0.42 ±  0.03 
1.37 ±0.11 
4.57 ± 0.24 
1.10 ±  0.07 
0.21 ± 0.02
The abscess-to-muscle ratios are shown in Figure 1A. 
After injection of m In-liposomes5 this ratio increased 
steadily from 7.9 at 2 hr postinjection to 33.9 at 48 hr 
postinjection. Both the increase over the 2-24-hr time pe­
riod (p < 0.013) and the increase over the 24-48-hr time 
period (p < 0.011) were statistically significant. Due to 
increasing activity in the abscess and decreasing activity in 
the blood, abscess-to-blood ratios also continued to in­
crease up to 3.3 at 48 hr postinjection (Fig. IB). The ab­
scess-to-muscle ratios as well as the abscess-to-blood ra­
tios 24 and 48 hr postinjection were significantly higher 
than those obtained with m In-IgG (p < 0.02).
The distribution of m In-liposomes was also studied 
scintigraphically. The acquired images were compared 
with the n lIn-IgG images. With m In-liposomes, the ab­
scess was visualized within 1 hr postinjection (Fig. 2).
Contrast between the infectious focus and the background 
improved with time. Besides high uptake in the abscess, 
marked localization was also observed in the spleen, which 
correlates with the biodistribution data. Quantification of 
the counts within the regions of interest, the abscess and 
the contralateral muscle indicated that the abscess-to- 
background ratio increased up to a value of 15.5 (Fig. 3A). 
In comparison to in In-IgG abscess-to-background ratios, 
the ratios obtained with liposomes were significantly higher 
(p < 0.04) from 4 hr postinjection onwards. The residual 
activity in the abscess (expressed as the percentage of the 
whole-body activity) also increased during the experiment 
(up to 18% at 48 hr postinjection) (Fig. 3B). From 24 hr 
onwards, the percentage residual activity in the abscess for 
lu In-liposomes was significantly higher than for m In-IgG 
(p < 0.04) (Fig. 3B). Indium-lll-liposomes and in In-IgG
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FIGURE 1. Abscess-to-muscle ratios (A) and abscess-to-blood ratios (B) at 2 hr, 24 hr and 48 hr postinjection for111 in-labeled PEGylated 
liposomes and 1111n-lgG. The biodistribution data of five rats per time point were used. Error bars represent standard deviations.
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FIGURE 2. Scintigrams of rats with unilateral S, aureus infections in calf muscle imaged 0 hr (=5 min), 1 hr, 4 hr, 12 hr, 24 hr and 48 hr 
postinjection of 111ln-labeled PEGylated liposomes (left) and 111ln-(gG (right),
were eliminated from the blood compartment at a similar 
rate: 50% of the activity was still circulating 20 hr postin­
jection. In fact, during the distribution phase (t1/2 a) clear­
ance of the m In-liposomes appeared to be slower, while 
the elimination rate (t1/2 fi) of the liposomes was faster (Fig. 
3C). Whole-body clearance of the u lIn for liposomes and 
IgG was minimal: over the 48-hr time interval less than 5% 
of the injected dose was excreted.
DISCUSSION
Sterically stabilized liposomes have been shown to lo­
calize preferentially in infectious foci (11,12) and radiola­
beling with gamma emitters might be useful tools for im­
aging infectious and inflammatory foci. In this study, we 
evaluated the potential of lllIn-labeled sterically stabilized 
liposomes to image bacterial infections of the left calf mus­
cle in rats.
Clearance of m In-labeled PEGylated liposomes from 
the blood was similar to u l In-IgG clearance in this model
(t1/2 ^  20 hr), allowing sufficient abscess uptake. The 
PEGylated liposomes showed preferential localization in 
the infected calf muscle. Recently, PEGylated liposomes 
labeled with " mTc have been proposed as a blood-pool 
marker in nuclear medicine (24). In a study of rabbits, 
Tilcock et al. (24) found that the half-life of " mTc-PEG- 
liposomes in the circulation was 5-10 hr. Although it is 
difficult to compare blood circulation times in different 
animal species, PEGylated liposomes apparently clear 
somewhat faster from the circulation, which might be due 
to the larger size (±200 nm) of the vesicles used. Recently, 
Goins et al. tested " mTc-liposomes (mean size 185 nm) in 
rats with 5. aureus infections (25). Their abscess-to-muscle 
ratios were high and in the same range as those reported in 
our study. In the Goins et al. study, however, urinary 
excretion amounted to 30% ID (as compared to <5% ID in 
our study), indicating that the non-PEGylated liposomes 
were less stable in vivo. In addition, the liposomal formu­
lation in the Goins study displayed an even higher splenic
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FIGURE 3. Quantitative analysis of the scintigraphic images of 
rats (three rats per group) injected with 111ln-liposomes (•) and 
111ln-lgG (O). Abscess-to-background ratios (A), retained activity in 
the abscess as percentage of residual whole-body activity (B) and 
activity in the blood-pool region (C) were determined for both agents. 
Blood-pool activity measured 5 min postinjection was set at 100%. 
Error bars represent standard deviations.
accumulation (up to 39% ID/g). Obviously, in clinical prac­
tice, " mTc is preferable to n iIn. We are conducting further 
studies to evaluate the characteristics of our liposomal 
formulation labeled with " mTc,
The mechanism of abscess accumulation of PEGylated 
liposomes has not been studied. Liposomes probably ex- 
travasate in areas of inflammation as a result of locally 
increased capillary permeability or through damaged endo­
thelial linings. Several studies have clearly demonstrated 
that liposomes are able to exploit this phenomenon of lo­
cally increased microvascular permeability to an increasing 
extent when the residence time in the blood is extended 
(12,26). Since other investigators have shown that the up­
take of long-circulating PEGylated liposomes by mono­
cytes is insignificant (27,28), the role of inflammatory cells 
in the extravasation of these liposomes is not expected to 
be of considerable importance. Studies in other infection
and/or inflammation models could indicate the importance 
of the presence of bacteria, phagocytotic cells, enhanced 
vascular permeability, etc.
S. aureus bacteria were chosen as the infectious agent 
because they provide reproducible focal infections in rats. 
Other groups have used E . coli as the infectious agent. 
Highly similar results have been obtained in both models 
with in In-IgG (29). How these radiolabeled liposomes lo­
calize other infections or inflammations remains to be de­
termined, but the answer could reveal important informa­
tion on the factors that determine liposomal accumulation.
Besides accumulation in the abscess, relatively high up­
take was also observed in the spleen. Uptake in the other 
nontarget organs was relatively low and decreased with 
time. Consequently, target-to-background ratios steadily 
increased during the 48-hr time interval after injection. 
Based on tissue counting, abscess-to-muscle ratios were 
approximately four times higher than those obtained with 
lu In-IgG in this model. Biodistribution data as well as 
scintigraphic results indicate that n lIn-liposomes have fa­
vorable imaging characteristics as compared to m In-IgG, 
mainly because the absolute uptake in the abscesses 1 and
2 days postinjection was more than twice as high.
One of the most striking characteristics of m In-labeled 
PEGylated liposomes in this model was the almost com­
plete absence of kidney uptake (less than 1 %ID/g), result­
ing in high abscess-to-kidney ratios. With m In-IgG, kidney 
activity exceeded 4% ID/g throughout the 48-hr time inter­
val in this model. In patients, abdominal abscess localiza­
tion with m In-IgG is hampered by the relatively high renal 
uptake (30). The reduced kidney uptake obtained with 
in In-liposomes cannot be explained by the low whole- 
body excretion because the same uptake was also ob­
served with in In-IgG. One might assume that the m In 
label remains associated with Desferal after release from 
the liposomes, resulting in rapid clearance to the urine 
without glomer retention of the radiolabel.
The abscess-to-blood ratios obtained with lu In-lipo- 
somes were also much higher than those obtained with 
lu In-IgG (3.3 versus 1.0 at 48 hr). Based on this favorable 
characteristic one might expect that PEGylated liposomes, 
like radiolabeled autologous leukocytes, may be used to 
image vascular lesions.
We believe that liposomes have two major advantages 
over radiolabeled leukocytes: (a) they are readily available 
because liposomes can be easily and rapidly reconstituted 
from their lyophilized form (31) and (b) liposomes will not 
contain blood-derived infectious agents (e.g., HBV, HIV).
A disadvantage of m In-liposomes imaging is high up­
take in the spleen. High splenic uptake was also found in 
other preclinical studies using PEGylated liposomes 
(12,29). As observed with U1ln-labeled autologous leuko­
cytes, the spleen will most likely be the organ that receives 
the highest radiation burden when lu In-liposomes are used 
for infection imaging (32). This uptake, however, hardly 
limits the clinical efficacy of m In-leukocytes (33). Hope­
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fully, this also holds true for radiolabeled PEGylated lipo­
somes .
CONCLUSION
The ideal universal radiopharmaceutical for infection 
and inflammation imaging does not exist. Our results indi­
cate that labeled PEGylated liposomes have attractive bio­
distribution and imaging characteristics, and further clini­
cal evaluation is warranted.
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